Patents by Inventor Michael Sierks

Michael Sierks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody based reagents that specifically recognize toxic oligomeric forms of tau
    Patent number: 12084490
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: September 10, 2024
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Huilai Tian
  • Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
    Patent number: 11549113
    Abstract: The present invention provides detection reagents and method for determining risk of traumatic brain injury (TBI) and/or susceptibility to neurodegenerative disease in a subject.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: January 10, 2023
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Lalitha Venkataraman, Wei Xin
  • DARPin REAGENTS THAT DISTINGUISH ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE SAMPLES
    Publication number: 20220276264
    Abstract: Disclosed are diagnostics kits and compositions for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.
    Type: Application
    Filed: March 4, 2022
    Publication date: September 1, 2022
    Inventors: Michael Sierks, Stephanie Williams
  • TARGETS AND METHODS OF DIAGNOSING, MONITORING AND TREATING FRONTOTEMPORAL DEMENTIA
    Publication number: 20220260593
    Abstract: Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 18, 2022
    Inventors: Michael Sierks, Stephanie Williams
  • DARPin reagents that distinguish Alzheimer's disease and Parkinson's disease samples
    Patent number: 11300576
    Abstract: Disclosed are diagnostics for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: April 12, 2022
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Michael Sierks, Stephanie Williams
  • Methods for detecting traumatic brain injury
    Patent number: 11175584
    Abstract: The present invention provides detection reagents and method for determining risk of traumatic brain injury (TBI), assessment of the amount of neuronal damage, and/or susceptibility to neurodegenerative disease in a subject.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 16, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Stephanie Williams
  • Antibody based reagents that specifically recognize toxic oligomeric forms of tau
    Patent number: 11046755
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: June 29, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Huilai Tian
  • Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43
    Patent number: 11022618
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: June 1, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Stephanie Williams, Lalitha Venkataraman
  • DARPin REAGENTS THAT DISTINGUISH ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE SAMPLES
    Publication number: 20200241014
    Abstract: Disclosed are diagnostics for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.
    Type: Application
    Filed: January 29, 2020
    Publication date: July 30, 2020
    Inventors: Michael Sierks, Stephanie Williams
  • Bispecific antibody fragments for neurological disease proteins and methods of use
    Patent number: 10407495
    Abstract: The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: September 10, 2019
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Yong Shen
  • ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID
    Publication number: 20190185553
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognizes oligomeric A? that is resistant to denaturation by SDS but does not bind monomeric, fibrillar or other oligomeric forms of A? that are generated in vitro.
    Type: Application
    Filed: February 1, 2019
    Publication date: June 20, 2019
    Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Srinath Kasturirangan
  • Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43
    Patent number: 10191068
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: January 29, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Stephanie Williams, Lalitha Venkataraman
  • METHODS FOR DETECTING TRAUMATIC BRAIN INJURY
    Publication number: 20180364577
    Abstract: The present invention provides detection reagents and method for determining risk of traumatic brain injury (TBI), assessment of the amount of neuronal damage, and/or susceptibility to neurodegenerative disease in a subject.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 20, 2018
    Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Stephanie Williams
  • Nanoscale process to generate reagents selective for individual protein variants
    Patent number: 9938330
    Abstract: The present invention provides devices and methods to separate and concentrate target protein species at a microliter scale and to generate reagents to those variants with exquisite selectivity for specific protein isoforms using only picograms of target material.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 10, 2018
    Assignee: Arizona Board of Regents, a Body Corporate of the State of Arizona, Acting for and on Behalf of Arizona State University
    Inventors: Michael Sierks, Mark Hayes
  • Antibody based reagents that specifically recognize toxic oligomeric forms of tau
    Patent number: 9915668
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: March 13, 2018
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Huilai Tian
  • ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID
    Publication number: 20170204170
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognizes oligomeric A? that is resistant to denaturation by SDS but does not bind monomeric, fibrillar or other oligomeric forms of A? that are generated in vitro.
    Type: Application
    Filed: December 23, 2016
    Publication date: July 20, 2017
    Applicant: Arizona Board of Regents, a Body Corporate of the State of Arizona, Acting For and On Behalf of
    Inventors: Michael Sierks, Srinath Kasturirangan
  • Antibody based reagents that specifically recognize toxic oligomeric forms of tau
    Patent number: 9650436
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomelic tau, fibrillar tau or non-disease associated forms of tau.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: May 16, 2017
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Huilai Tian
  • BISPECIFIC ANTIBODY FRAGMENTS FOR NEUROLOGICAL DISEASE PROTEINS AND METHODS OF USE
    Publication number: 20170101463
    Abstract: The present invention relates to therapeutic agents comprising bispecific recombinant antibody fragments to selectively clear a protein associated with a neurological disease and methods of use of these therapeutic agents to treat neurological diseases.
    Type: Application
    Filed: October 24, 2016
    Publication date: April 13, 2017
    Applicant: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF
    Inventors: Michael Sierks, Yong Shen
  • Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid
    Patent number: 9567393
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognizes oligomeric A? that is resistant to denaturation by SDS but does not bind monomeric, fibrillar or other oligomeric forms of A? that are generated in vitro.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: February 14, 2017
    Inventors: Michael Sierks, Srinath Kasturirangan
  • Nanoscale process to generate reagents selective for individual protein variants
    Patent number: RE49625
    Abstract: The present invention provides devices and methods to separate and concentrate target protein species at a microliter scale and to generate reagents to those variants with exquisite selectivity for specific protein isoforms using only picograms of target material.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: August 29, 2023
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA
    Inventors: Michael Sierks, Mark Hayes